NCT00047463

Brief Summary

The purpose of this trial is to work out design issues prior to conducting a definitive phase 3 trial to determine whether treating sleep-related breathing disorders in people with epilepsy results in improvement in seizure control or an improvement in alertness during the day.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
68

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Sep 2002

Longer than P75 for phase_2

Geographic Reach
1 country

4 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2002

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

October 7, 2002

Completed
1 day until next milestone

First Posted

Study publicly available on registry

October 8, 2002

Completed
5.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2008

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2008

Completed
2.8 years until next milestone

Results Posted

Study results publicly available

May 3, 2011

Completed
Last Updated

July 21, 2016

Status Verified

July 1, 2016

Enrollment Period

5.8 years

First QC Date

October 7, 2002

Results QC Date

November 18, 2009

Last Update Submit

July 20, 2016

Conditions

Keywords

epilepsysleep apneaobstructive sleep apneacontinuous positive airway pressureCPAP

Outcome Measures

Primary Outcomes (1)

  • CPAP Adherence/Tolerance as Measured by Proportion of Nights Used

    This measure quantifies how well patients use their CPAP. The standard unit of measurement is proportion of nights that the CPAP is used by a participant (total nights used/total nights the device could have been used), averaged across all participants . Data were downloaded by a card placed in the CPAP machine reflecting use over the entire 10 weeks.

    10 weeks

Secondary Outcomes (2)

  • Number of Patients That Were Able to be Blinded to CPAP or Placebo CPAP

    10 weeks

  • Number of Patients Requiring Only One Night of Baseline Sleep Study to Detect Sleep Apnea

    prior to randomization

Study Arms (2)

CPAP active comparator

ACTIVE COMPARATOR

continuous positive airway pressure (CPAP)

Device: continuous positive airway pressure (CPAP)

CPAP Placebo

PLACEBO COMPARATOR

Placebo-CPAP

Device: Placebo-CPAP

Interventions

a mask treatment for sleep apnea

CPAP active comparator

Placebo-CPAP

CPAP Placebo

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age of 18 years or older.
  • A history supportive of obstructive sleep apnea.
  • Subject is able and willing to provide informed consent and to cooperate with polysomnography.
  • Four or more quantifiable seizures per month.
  • Subjects and their physicians agree to have their medication regimens optimized so that they are on the best regimen titrated to therapeutic benefit prior to the baseline phase of the study.

You may not qualify if:

  • Seizures secondary to drugs, alcohol, infection, neoplasia, demyelination, metabolic illness, or progressive degenerative disease.
  • Non-epileptic spells (e.g., pseudoseizures) alone or in combination with epileptic seizures.
  • Narcolepsy or another primary sleep disorder that requires intervention with medications and which may affect results of study (e.g., severe periodic limb movement disorder).
  • Effectively treated OSA or prior exposure to continuous positive airway pressure.
  • History of poor compliance with antiepileptic medications.
  • Current treatment with the vagus nerve stimulator.
  • Pregnancy.
  • A significant history of medical or psychiatric disease which may impair participation in the trial.
  • A history of alcohol or drug abuse during the one-year period prior to trial participation.
  • Evidence of medical instability (e.g., congestive heart failure, cardiac arrhythmias, pulmonary disease) due to obstructive sleep apnea.
  • Subjects who are unaware of the majority of their seizures and lack a reliable witness.
  • Greater than ten seizures a day.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

University of Michigan

Ann Arbor, Michigan, 48109, United States

Location

University of North Carolina

Chapel Hill, North Carolina, 27599, United States

Location

Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States

Location

Vanderbilt University

Nashville, Tennessee, 37232, United States

Location

Related Publications (2)

  • Malow BA, Foldvary-Schaefer N, Vaughn BV, Selwa LM, Chervin RD, Weatherwax KJ, Wang L, Song Y. Treating obstructive sleep apnea in adults with epilepsy: a randomized pilot trial. Neurology. 2008 Aug 19;71(8):572-7. doi: 10.1212/01.wnl.0000323927.13250.54.

  • Selwa LM, Marzec ML, Chervin RD, Weatherwax KJ, Vaughn BV, Foldvary-Schaefer N, Wang L, Song Y, Malow BA. Sleep staging and respiratory events in refractory epilepsy patients: Is there a first night effect? Epilepsia. 2008 Dec;49(12):2063-8. doi: 10.1111/j.1528-1167.2008.01681.x. Epub 2008 May 29.

MeSH Terms

Conditions

EpilepsySleep Apnea SyndromesSleep Apnea, Obstructive

Interventions

Continuous Positive Airway Pressure

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System DiseasesApneaRespiration DisordersRespiratory Tract DiseasesSleep Disorders, IntrinsicDyssomniasSleep Wake Disorders

Intervention Hierarchy (Ancestors)

Positive-Pressure RespirationRespiration, ArtificialAirway ManagementTherapeuticsRespiratory Therapy

Limitations and Caveats

Being a pilot study with a relatively small sample size, we were unable to isolate the effects of specific medications or seizure types on the presence of sleep apnea.

Results Point of Contact

Title
Beth Malow/Principal Investigator
Organization
Vanderbilt University

Study Officials

  • Beth Malow, M.D., M.S.

    Vanderbilt University

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of Neurology

Study Record Dates

First Submitted

October 7, 2002

First Posted

October 8, 2002

Study Start

September 1, 2002

Primary Completion

July 1, 2008

Study Completion

July 1, 2008

Last Updated

July 21, 2016

Results First Posted

May 3, 2011

Record last verified: 2016-07

Locations